Sirna hopes to create drugs based on this process of RNA interference (RNAi). Though it's still a young technology, RNAi was dubbed 2002's breakthrough of the year by Science magazine, and it's already considered indispensable in many drug-discovery programs for the validation of promising drug targets.
So far, Sirna has advanced just one drug into clinical trials. Sirna-027 is directed at age-related macular degeneration (AMD), a leading cause of blindness among the elderly. It recently completed a successful phase 1 trial, and it's expected to progress to phase 2 later this year. Allergan
Sirna Therapeutics' preclinical pipeline is robust. Sirna-034, directed at hepatitis C, should enter the clinic after the completion of its investigational new drug filing, expected later this year. Sirna-034 is a combination of two small interfering RNAs and a nanoparticle delivery vehicle. It proved effective at decreasing viral counts in infected primate models. Treatment of hepatitis C would require systemic delivery of Sirna-034 to humans, a traditionally large hurdle for siRNA and related antisense-based drugs. In addition to Sirna-034, the company has pre-clinical programs directed at treatments for Huntington's disease, hair removal, and diabetes.
The company also recently signed a collaboration agreement with GlaxoSmithKline
Sirna Therapeutics currently has more than $92 million in cash, with no debt. Its war chest was boosted by a $47.4 million follow-on offering in May 2006. Given management's projected annual burn rate of $30 million-$33 million, that should give the company adequate funds to demonstrate the effectiveness of a few more of its therapies in clinical trials. Signing additional partnerships and collaborations should bolster Sirna's development program as well.
While drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities. Still, Fools with an eye toward the future should keep tabs on RNAi research firms like Sirna, and the developments they discover.
Get the latest updates on biotechnology breakthroughs and other high-tech stocks with a free 30-day trial to Motley Fool Rule Breakers.
GlaxoSmithKline is a Motley Fool Income Investor selection; Merck was a former Income Investor pick.
Fool contributor Ralph Casale is constantly trying to keep all his genes from getting knocked down. He owns shares in GlaxoSmithKline, but holds no financial position in any other firm mentioned. The Fool has a disclosure policy.
More from The Motley Fool
1 Stock I'm Buying More Of in 2018
One airline stock is trading for less than 7 times trailing earnings -- even though the company is likely to achieve double-digit EPS growth in 2018.
Vermont Is Legalizing Marijuana in a Unique Way
No state has ever done this before, and it could pave the way for other states to follow in its footsteps.
This Top Dividend Growth Stock Sees No End in Sight
After growing its already lucrative payout 30% last year, this 4.6% yielder sees at least 20% annual growth for the next five years.